Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5

Journal of Clinical Investigation

Volumn 109, Issue 7, 2002, Pages 871-882

  Nakamura, Hideo ^a   Kasuya, Hideki ^a   Mullen, John T ^a   Yoon, Sam S ^a   Pawlik, Timothy M ^a   Chandrasekhar, Soundararajalu ^a   Donahue, James M ^a   Antonio Chiocca, E ^a   Chung, Richard Y ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; GENE PRODUCT; INITIATION FACTOR 2; PROTEIN MYB34.5; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DESTRUCTION; CELL DIVISION; COLON CARCINOMA; CONTROLLED STUDY; DEFENSE MECHANISM; GENE DELETION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; LIVER CELL; LIVER METASTASIS; MOUSE; NONHUMAN; ONCOGENE MYB; PORTAL VEIN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFECT; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION; VIRUS EXPRESSION; VIRUS INFECTION; VIRUS MUTANT; VIRUS VIRULENCE; WILD TYPE;

EID: 0036212495     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0210623     Document Type: Article

References (61)

1. Human gene marker/therapy clinical protocols
2. Gene therapy for cancer: What have we done and where are we going?
3. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
4. ONYX-015: Clinical data are encouraging
5. Experimental therapy of human glioma by means of a genetically engineered virus mutant
6. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
7. Reovirus therapy of tumors with activated Ras pathway
8. Tumours of the liver - Pathological aspects
9. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
10. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
11. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system
12. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain rumors
13. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector
14. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene- mediated virulence toward tumor and cycling cells
15. Mapping of herpes simplex virus-1 neurovitulence to gamma 134.5, a gene nonessential for growth in culture
16. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells
17. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase lalpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase
18. The gamma 134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells
19. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant
20. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy
21. Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine
22. Mutations in the double-stranded RNA-activated protein kinase insert region that uncouple catalysis from eIF2alpha binding
23. Dietary fat elevates hepatic apoA-I production by increasing the fraction of apolipoprotein A-I mRNA in the translating pool
24. Differential effect of Mn2+ on the hemin-controlled translational repressor and the double-stranded RNA-activated inhibitor
25. The acidic aminoerminal region of herpes simplex virus type 1 alpha protein ICP27 is required for an essential lyric function
26. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
27. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection
28. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
29. Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice
30. A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice
31. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
32. Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern Hispanic and non-Hispanic white women
33. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
34. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
35. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare
36. Treatment of human cancer with mumps virus
37. Delivery of molecular medicine to solid tumors
38. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
39. Transcriptional targeting of herpes simplex virus for cell-specific replication
40. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors
41. Acyclovir-a review of the preclinical and early clinical data of a new antiherpes drug
42. Replication-defective-mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection
43. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
44. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
45. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1
46. Interferon and antibody production in mice with herpes simplex skin infections
47. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase
48. PKR, apoptosis and cancer
49. In vitro analysis of virus-associated RNA I (VAI RNA): Inhibition of the double-stranded RNA-activated protein kinase PKR by VAI RNA mutants correlates with the in vivo phenotype and the structural integrity of the central domain
50. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR
51. The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins
52. The 58-kDa cellular inhibitor of the double stranded RNA-dependent protein kinase requires the tetratricopeptide repeat 6 and DnaJ motifs to stimulate protein synthesis in vivo
53. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
54. The E3L and K3L, vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by differenr mechanisms
55. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
56. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
57. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
58. Clinical perspective of human colorectal cancer metastasis
59. Surgical treatment and other regional treatments for colorectat cancer liver metastases
60. Mapping the in vivo distribution of herpes simplex virions
61. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells